Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia.

Spina F, Rezzonico F, Farina L, Corradini P.

Eur J Haematol. 2013 Apr;90(4):340-4. doi: 10.1111/ejh.12068. Epub 2013 Feb 14.

PMID:
23281656
2.

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.

Chanan-Khan A, Miller KC, Musial L, Lawrence D, Padmanabhan S, Takeshita K, Porter CW, Goodrich DW, Bernstein ZP, Wallace P, Spaner D, Mohr A, Byrne C, Hernandez-Ilizaliturri F, Chrystal C, Starostik P, Czuczman MS.

J Clin Oncol. 2006 Dec 1;24(34):5343-9. Epub 2006 Nov 6.

3.

Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation.

Farina L, Carniti C, Dodero A, Vendramin A, Raganato A, Spina F, Patriarca F, Narni F, Benedetti F, Olivieri A, Corradini P.

Haematologica. 2009 May;94(5):654-62. doi: 10.3324/haematol.2008.000273. Epub 2009 Apr 18.

4.

Immunomodulators in chronic lymphocytic leukemia: where does lenalidomide belong?

Brown JR.

Leuk Lymphoma. 2010 Aug;51(8):1382-5. doi: 10.3109/10428194.2010.496017.

PMID:
20624030
5.

Lenalidomide alone and in combination for chronic lymphocytic leukemia.

Chen CI.

Curr Hematol Malig Rep. 2013 Mar;8(1):7-13. doi: 10.1007/s11899-012-0146-x. Review.

PMID:
23254517
6.

Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.

Chen CI, Bergsagel PL, Paul H, Xu W, Lau A, Dave N, Kukreti V, Wei E, Leung-Hagesteijn C, Li ZH, Brandwein J, Pantoja M, Johnston J, Gibson S, Hernandez T, Spaner D, Trudel S.

J Clin Oncol. 2011 Mar 20;29(9):1175-81. doi: 10.1200/JCO.2010.29.8133. Epub 2010 Dec 28.

7.

Detection of minimal residual disease in B chronic lymphocytic leukemia (CLL).

Magnac C, Sutton L, Cazin B, Laurent C, Binet JL, Merle-Béral H, Dighiero G, Maloum K.

Hematol Cell Ther. 1999 Feb;41(1):13-8.

PMID:
10193641
8.

Lenalidomide in the treatment of chronic lymphocytic leukemia.

Gentile M, Recchia AG, Vigna E, Mazzone C, Lucia E, Gigliotti V, Bossio S, Madeo A, Morabito L, Servillo P, Franzese S, Caruso N, De Stefano L, Bisconte MG, Gentile C, Morabito F.

Expert Opin Investig Drugs. 2011 Feb;20(2):273-86. doi: 10.1517/13543784.2011.546343. Epub 2011 Jan 10. Review.

PMID:
21214505
9.

Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics.

Sher T, Miller KC, Lawrence D, Whitworth A, Hernandez-Ilizaliturri F, Czuczman MS, Miller A, Lawrence W, Bilgrami SA, Sood R, Wood MT, Block AW, Lee K, Chanan-Khan AA.

Leuk Lymphoma. 2010 Jan;51(1):85-8. doi: 10.3109/10428190903406806.

PMID:
20055660
10.

Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.

Awan FT, Johnson AJ, Lapalombella R, Hu W, Lucas M, Fischer B, Byrd JC.

Leuk Lymphoma. 2010 Jan;51(1):27-38. doi: 10.3109/10428190903350405. Review.

11.

Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.

Giannopoulos K, Mertens D, Stilgenbauer S.

Expert Opin Pharmacother. 2011 Dec;12(18):2857-64. doi: 10.1517/14656566.2011.635644. Review.

PMID:
22098228
12.

Evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical and bone-marrow remission using CD5-CD19 markers and PCR study of gene rearrangements.

Vuillier F, Claisse JF, Vandenvelde C, Travade P, Magnac C, Chevret S, Desablens B, Binet JL, Dighiero G.

Leuk Lymphoma. 1992 Jun;7(3):195-204.

PMID:
1282428
13.

Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p.

Arumainathan A, Kalakonda N, Pettitt AR.

Eur J Haematol. 2011 Oct;87(4):372-5. doi: 10.1111/j.1600-0609.2011.01667.x. Epub 2011 Aug 11.

PMID:
21679253
14.

Concurrent B-cell chronic lymphocytic leukemia and multiple myeloma treated successfully with lenalidomide.

Srinivasan S, Schiffer CA.

Leuk Res. 2009 Apr;33(4):561-4. doi: 10.1016/j.leukres.2008.06.024. Epub 2008 Aug 3.

PMID:
18676017
15.

Immunomodulatory drugs in chronic lymphocytic leukemia: a new treatment paradigm.

Molica S.

Leuk Lymphoma. 2007 May;48(5):866-9. Review.

PMID:
17487728
16.

Lenalidomide and chronic lymphocytic leukemia.

González-Rodríguez AP, Payer AR, Acebes-Huerta A, Huergo-Zapico L, Villa-Alvarez M, Gonzalez-García E, Gonzalez S.

Biomed Res Int. 2013;2013:932010. doi: 10.1155/2013/932010. Epub 2013 Sep 19. Review.

17.

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.

Ferrajoli A, Lee BN, Schlette EJ, O'Brien SM, Gao H, Wen S, Wierda WG, Estrov Z, Faderl S, Cohen EN, Li C, Reuben JM, Keating MJ.

Blood. 2008 Jun 1;111(11):5291-7. doi: 10.1182/blood-2007-12-130120. Epub 2008 Mar 11.

18.

Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia.

Strati P, Keating MJ, Wierda WG, Badoux XC, Calin S, Reuben JM, O'Brien S, Kornblau SM, Kantarjian HM, Gao H, Ferrajoli A.

Blood. 2013 Aug 1;122(5):734-7. doi: 10.1182/blood-2013-04-495341. Epub 2013 Jun 25.

19.

Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol.

Noy A, Verma R, Glenn M, Maslak P, Rahman ZU, Keenan JR, Weiss M, Filippa D, Zelenetz AD.

Blood. 2001 Apr 1;97(7):1929-36.

20.

The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).

Dawar R, Hernandez-Ilizaliturri F.

Best Pract Res Clin Haematol. 2012 Jun;25(2):185-90. doi: 10.1016/j.beha.2012.04.005. Epub 2012 May 18. Review.

PMID:
22687454
Items per page

Supplemental Content

Write to the Help Desk